Participating in a clinical trial or research study is a valuable health care option available to many patients at The Nebraska Medical Center. Participants are able to take a more active role in their own health care, gain access to new drugs and treatments before they become widely available, and help other patients by contributing to medical research.
The Nebraska Medical Center participates in many of the latest and most innovative research studies, which in turn provide patients access to the newest treatments. Research is a direct link to improved techniques and increased success in transplantations and the treatment of liver diseases.
Once a patient has been evaluated and approved for a transplant, they may be eligible for participation in a clinical trial. Patients deemed eligible to participate in a clinical trial have the opportunity to review the study protocol to determine what is expected. The protocol will list details including the schedule of tests, procedures, medications, dosages, schedule of doctor appointments and the duration of the study.
Choosing to enroll in a research study is a personal decision. It requires careful consideration of the potential advantages and disadvantages. If a patient decides to participate in the study, they will be asked to sign an informed consent document. This document is not a contract, and the patient may withdraw at any time. The information on this page describes investigational programs the liver transplant program currently participates in to help advance transplantation success.
Please contact our Clinical Studies Program Coordinator regarding any questions or for further information regarding the available research studies:
Kris Seipel
402-559-6022
kseipel@unmc.edu
More information on any sponsored study is also available at www.clinicaltrials.gov
Liver Protocols:
Facilitated Access Program to Provide Everolimus (RAD) for Maintenance Patients Completing Therapy in RAD Trials in Solid Organ Transplantation.
Principal Investigator:
Alan Langnas, DO
Description:
The major goal of this research is to continue to monitor long-term safety and efficacy of Everolimus in recipients of solid organ transplants. (Follow-up umbrella study to previous RAD study)
Randomized Single-Center Trial Comparing Thymoglobulin Induction Therapy and Delayed Initiation of Tacrolimus to No Induction with Immediate Initiation of Tacrolimus in Liver Transplant Recipients to Assess the Impact on Renal Function.
Principal Investigator:
Wendy Grant, MD
Description:
The major goal of this study is explore the safety and efficacy of Thymoglobulin induction therapy in liver transplant patients on renal function when used with a Tacrolimus-sparing maintenance therapy compared to a Tacrolimus-based standard therapy without induction. This study is investigator-initiated with the Thymoglobulin supplied by the Genzyme Corporation.
Omegaven - Prospective Evaluation of Prenteral Omega-3 Fatty Acid Preparation (Omegaven) in Therapy of Patients with TPN-Induced Cholestasis
Principal Investigator:
David Mercer, MD, PhD
Pediatric Liver Unresectable Tumor Observatory (PLUTO), a Multi-Center Research Registry to Collect Scientific Data on Pediatric Liver Tumors
Principal Investigator:
Alan Langnas, DO
Description:
The purpose of this registry is to enter medical information, from patients with unresectable liver tumors, into a registry so that the information can be used to conduct future research studies at increasing knowledge about pediatric liver tumors.
Please contact our Clinical Studies Program Coordinator regarding any questions or for further information regarding the available research studies:
Kris Seipel
402-559-6022
kseipel@unmc.edu
More information on any sponsored study is also available at www.clinicaltrials.gov
Transplant Center
